My Quote Request
6505-01-487-6727
20 Products
NDC00045-1530-10
LEVOFLOXACIN TABLET
NSN, MFG P/N
6505014876727
NSN
6505-01-487-6727
MFG
MCNEIL PHARMACEUTICAL CO
Description
GENERAL CHARACTERISTICS ITEM DESCRIPTION: 750 MG LEVOFLOXACIN; UNIT DOSE, 100 TABLETS PER PKG
III PART NAME ASSIGNED BY CONTROLLING AGENCY: LEVOFLOXACIN TABLETS 750MG 100S PG
Related Searches:
01-0440
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,ADSORBED,USP
NSN, MFG P/N
6505014888943
NSN
6505-01-488-8943
01-0440
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,ADSORBED,USP
NSN, MFG P/N
6505014888943
NSN
6505-01-488-8943
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: DIPHTHERIA & TITANUS TOXOIDS & PERTUSSIS VAC ADSORBED USP 10S
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: INDICATED FOR ACTIVE IMMUNIZATIONS AGAINST DIPHTHERIA, TETANUS AND PERTUSSIS SIMULTANEOUSLY IN INFANTS AND CHILDREN 6 WEEKS TO 7 YEARS OF AGE
IMMEDIATE CONTAINER QUANTITY: 10
IMMEDIATE CONTAINER TYPE: VIAL
SPECIAL FEATURES: EACH 0.5 ML DOSE IS FORMULATED TO CONTAIN 6.7 LF OF DIPHTHERIA TOXOID AND 5 LF OF TETANUS TOXOID AND 46.8 MICROGRAMS OF PERTUSSIS; 10 SINGLE DOSE VIALS PER PACKAGE; CONTAINS NO PRESERVATIVE; STORE BETWEEN 2-8 DEG C
UNIT PACKAGE TYPE: PACKAGE
Related Searches:
NDC49281-0298-10
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,ADSORBED,USP
NSN, MFG P/N
6505014888943
NSN
6505-01-488-8943
NDC49281-0298-10
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,ADSORBED,USP
NSN, MFG P/N
6505014888943
NSN
6505-01-488-8943
MFG
SANOFI PASTEUR INC.
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: DIPHTHERIA & TITANUS TOXOIDS & PERTUSSIS VAC ADSORBED USP 10S
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: INDICATED FOR ACTIVE IMMUNIZATIONS AGAINST DIPHTHERIA, TETANUS AND PERTUSSIS SIMULTANEOUSLY IN INFANTS AND CHILDREN 6 WEEKS TO 7 YEARS OF AGE
IMMEDIATE CONTAINER QUANTITY: 10
IMMEDIATE CONTAINER TYPE: VIAL
SPECIAL FEATURES: EACH 0.5 ML DOSE IS FORMULATED TO CONTAIN 6.7 LF OF DIPHTHERIA TOXOID AND 5 LF OF TETANUS TOXOID AND 46.8 MICROGRAMS OF PERTUSSIS; 10 SINGLE DOSE VIALS PER PACKAGE; CONTAINS NO PRESERVATIVE; STORE BETWEEN 2-8 DEG C
UNIT PACKAGE TYPE: PACKAGE
Related Searches:
TRIPEDIA
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,ADSORBED,USP
NSN, MFG P/N
6505014888943
NSN
6505-01-488-8943
TRIPEDIA
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,ADSORBED,USP
NSN, MFG P/N
6505014888943
NSN
6505-01-488-8943
MFG
SANOFI PASTEUR INC.
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: DIPHTHERIA & TITANUS TOXOIDS & PERTUSSIS VAC ADSORBED USP 10S
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: INDICATED FOR ACTIVE IMMUNIZATIONS AGAINST DIPHTHERIA, TETANUS AND PERTUSSIS SIMULTANEOUSLY IN INFANTS AND CHILDREN 6 WEEKS TO 7 YEARS OF AGE
IMMEDIATE CONTAINER QUANTITY: 10
IMMEDIATE CONTAINER TYPE: VIAL
SPECIAL FEATURES: EACH 0.5 ML DOSE IS FORMULATED TO CONTAIN 6.7 LF OF DIPHTHERIA TOXOID AND 5 LF OF TETANUS TOXOID AND 46.8 MICROGRAMS OF PERTUSSIS; 10 SINGLE DOSE VIALS PER PACKAGE; CONTAINS NO PRESERVATIVE; STORE BETWEEN 2-8 DEG C
UNIT PACKAGE TYPE: PACKAGE
Related Searches:
754HC611
ISOPROPYL ALCOHOL,USP
NSN, MFG P/N
6505014895474
NSN
6505-01-489-5474
MFG
TECHNI-TOOL INC
Description
PRIMARY CONTAINER CONTENT QUANTITY: 1.000 GALLONS
PRIMARY CONTAINER TYPE: CAN
SPECIAL FEATURES: 99.0 PERCENT PURE ANHYDROUS ISOPROPANOL FOR ALL-PURPOSE CLEANING AND REMOVAL OF FLUXES, LIGHT OILS AND SOILS
Related Searches:
01-0492
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
01-0492
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
FEATURES PROVIDED: STERILE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: RED BLOOD CELL REJUVENATING SOLUTION 50ML VIAL 12S
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: PROCESSING SOLUTION, RED BLOOD CELL; REJUVENATING SOLUTION FOR FROZEN BLOOD, REJUVESOL
PRIMARY CONTAINER CONTENT QUANTITY: 50.000 MILLILITERS
PRIMARY CONTAINER TYPE: VIAL, GLASS
SPECIAL FEATURES: CONTAINS SODIUM PYRUVATE 550 MG, INOSINE 1.346 G, ADENINE 0.034 G; NDC NUMBER IS 23731-7000-05; PRODUCT SHOULD BE STORED AT 16 TO 26 DEGREES C; FOR USE IN THE EXTRACORPOREAL REJEVENATION OF RED BLOOD CELLS PRIOR TO TO FREEZING; IT SHOULD NEVER BE DIRECTLY
TOTAL PRIMARY CONTAINER QUANTITY: 12
~1: ADMINISTERED IN HUMANS; CONTAINS NO BACTERIOSTAT OR ANTIMICROBIAL AGENTS AND IT IS INTENDED FOR SINGLE USE ONLY; RECOMMENDED THAT THE ENTIRE 50 ML OF REJUVESOL BE ADDED TO A SMALLER THAN NORMAL RBCC AS LONG AS THE PREREJUVENATION NET PACKED CELL WEIGHT IS
~2: GREATER THAN 110 GRAMS
Related Searches:
7012
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
7012
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
MFG
CYTOSOL LABORATORIES INC
Description
FEATURES PROVIDED: STERILE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: RED BLOOD CELL REJUVENATING SOLUTION 50ML VIAL 12S
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: PROCESSING SOLUTION, RED BLOOD CELL; REJUVENATING SOLUTION FOR FROZEN BLOOD, REJUVESOL
PRIMARY CONTAINER CONTENT QUANTITY: 50.000 MILLILITERS
PRIMARY CONTAINER TYPE: VIAL, GLASS
SPECIAL FEATURES: CONTAINS SODIUM PYRUVATE 550 MG, INOSINE 1.346 G, ADENINE 0.034 G; NDC NUMBER IS 23731-7000-05; PRODUCT SHOULD BE STORED AT 16 TO 26 DEGREES C; FOR USE IN THE EXTRACORPOREAL REJEVENATION OF RED BLOOD CELLS PRIOR TO TO FREEZING; IT SHOULD NEVER BE DIRECTLY
TOTAL PRIMARY CONTAINER QUANTITY: 12
~1: ADMINISTERED IN HUMANS; CONTAINS NO BACTERIOSTAT OR ANTIMICROBIAL AGENTS AND IT IS INTENDED FOR SINGLE USE ONLY; RECOMMENDED THAT THE ENTIRE 50 ML OF REJUVESOL BE ADDED TO A SMALLER THAN NORMAL RBCC AS LONG AS THE PREREJUVENATION NET PACKED CELL WEIGHT IS
~2: GREATER THAN 110 GRAMS
Related Searches:
NDC23731-7000-05
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
NDC23731-7000-05
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
MFG
CYTOSOL LABORATORIES INC
Description
FEATURES PROVIDED: STERILE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: RED BLOOD CELL REJUVENATING SOLUTION 50ML VIAL 12S
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: PROCESSING SOLUTION, RED BLOOD CELL; REJUVENATING SOLUTION FOR FROZEN BLOOD, REJUVESOL
PRIMARY CONTAINER CONTENT QUANTITY: 50.000 MILLILITERS
PRIMARY CONTAINER TYPE: VIAL, GLASS
SPECIAL FEATURES: CONTAINS SODIUM PYRUVATE 550 MG, INOSINE 1.346 G, ADENINE 0.034 G; NDC NUMBER IS 23731-7000-05; PRODUCT SHOULD BE STORED AT 16 TO 26 DEGREES C; FOR USE IN THE EXTRACORPOREAL REJEVENATION OF RED BLOOD CELLS PRIOR TO TO FREEZING; IT SHOULD NEVER BE DIRECTLY
TOTAL PRIMARY CONTAINER QUANTITY: 12
~1: ADMINISTERED IN HUMANS; CONTAINS NO BACTERIOSTAT OR ANTIMICROBIAL AGENTS AND IT IS INTENDED FOR SINGLE USE ONLY; RECOMMENDED THAT THE ENTIRE 50 ML OF REJUVESOL BE ADDED TO A SMALLER THAN NORMAL RBCC AS LONG AS THE PREREJUVENATION NET PACKED CELL WEIGHT IS
~2: GREATER THAN 110 GRAMS
Related Searches:
REJUVESOL
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
REJUVESOL
RED BLOOD CELL REJUVENATING SOLUTION
NSN, MFG P/N
6505014904387
NSN
6505-01-490-4387
MFG
CYTOSOL LABORATORIES INC
Description
FEATURES PROVIDED: STERILE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: RED BLOOD CELL REJUVENATING SOLUTION 50ML VIAL 12S
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: PROCESSING SOLUTION, RED BLOOD CELL; REJUVENATING SOLUTION FOR FROZEN BLOOD, REJUVESOL
PRIMARY CONTAINER CONTENT QUANTITY: 50.000 MILLILITERS
PRIMARY CONTAINER TYPE: VIAL, GLASS
SPECIAL FEATURES: CONTAINS SODIUM PYRUVATE 550 MG, INOSINE 1.346 G, ADENINE 0.034 G; NDC NUMBER IS 23731-7000-05; PRODUCT SHOULD BE STORED AT 16 TO 26 DEGREES C; FOR USE IN THE EXTRACORPOREAL REJEVENATION OF RED BLOOD CELLS PRIOR TO TO FREEZING; IT SHOULD NEVER BE DIRECTLY
TOTAL PRIMARY CONTAINER QUANTITY: 12
~1: ADMINISTERED IN HUMANS; CONTAINS NO BACTERIOSTAT OR ANTIMICROBIAL AGENTS AND IT IS INTENDED FOR SINGLE USE ONLY; RECOMMENDED THAT THE ENTIRE 50 ML OF REJUVESOL BE ADDED TO A SMALLER THAN NORMAL RBCC AS LONG AS THE PREREJUVENATION NET PACKED CELL WEIGHT IS
~2: GREATER THAN 110 GRAMS
Related Searches:
01-0551
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014906146
NSN
6505-01-490-6146
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 500.000 MILLIGRAMS CIPROFLOXACIN ACTIVE INGREDIENT
FEATURES PROVIDED: UNIT DOSE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: CIPROFLOXCIN TABLETS USP 500MG I.S. 460 PER STRIP 10 STRIPS PG 4600S
PRIMARY CONTAINER CONTENT QUANTITY: 4600.000 TABLETS
PRIMARY CONTAINER TYPE: STRIP
SPECIAL FEATURES: 460 TABLETS PER STRIP, 10 STRIPS PER PKG
TOTAL PRIMARY CONTAINER QUANTITY: 10
Related Searches:
CIPRO
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014906146
NSN
6505-01-490-6146
MFG
BAYER HEALTHCARE LLC DBA DIABETES CARE
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 500.000 MILLIGRAMS CIPROFLOXACIN ACTIVE INGREDIENT
FEATURES PROVIDED: UNIT DOSE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: CIPROFLOXCIN TABLETS USP 500MG I.S. 460 PER STRIP 10 STRIPS PG 4600S
PRIMARY CONTAINER CONTENT QUANTITY: 4600.000 TABLETS
PRIMARY CONTAINER TYPE: STRIP
SPECIAL FEATURES: 460 TABLETS PER STRIP, 10 STRIPS PER PKG
TOTAL PRIMARY CONTAINER QUANTITY: 10
Related Searches:
NDC00026-8513-77
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014906146
NSN
6505-01-490-6146
NDC00026-8513-77
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014906146
NSN
6505-01-490-6146
MFG
BAYER PHARMACEUTICALS CORPORATION
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 500.000 MILLIGRAMS CIPROFLOXACIN ACTIVE INGREDIENT
FEATURES PROVIDED: UNIT DOSE
III PART NAME ASSIGNED BY CONTROLLING AGENCY: CIPROFLOXCIN TABLETS USP 500MG I.S. 460 PER STRIP 10 STRIPS PG 4600S
PRIMARY CONTAINER CONTENT QUANTITY: 4600.000 TABLETS
PRIMARY CONTAINER TYPE: STRIP
SPECIAL FEATURES: 460 TABLETS PER STRIP, 10 STRIPS PER PKG
TOTAL PRIMARY CONTAINER QUANTITY: 10
Related Searches:
0065079525
OPHTHALMIC IRRIGATING SOLUTION
NSN, MFG P/N
6505014907160
NSN
6505-01-490-7160
0065079525
OPHTHALMIC IRRIGATING SOLUTION
NSN, MFG P/N
6505014907160
NSN
6505-01-490-7160
MFG
ALCON LABORATORIES INC .
Description
ADMINISTRATION: INTRAOCULAR
PRIMARY CONTAINER CONTENT QUANTITY: 250.000 MILLILITERS
PRIMARY CONTAINER TYPE: BOTTLE
SPECIAL FEATURES: PLAIN BSS
Related Searches:
01-0432
POLIOVIRUS VACCINE INACTIVATED,USP
NSN, MFG P/N
6505014910528
NSN
6505-01-491-0528
01-0432
POLIOVIRUS VACCINE INACTIVATED,USP
NSN, MFG P/N
6505014910528
NSN
6505-01-491-0528
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: POLIOVIRUS VACCINE INACTIVATED MODIFIED 10 DOSE VIAL
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: POLIO VIRUS VACCINE, INACTIVATED
IMMEDIATE CONTAINER QUANTITY: 1
IMMEDIATE CONTAINER TYPE: VIAL
QUANTITY WITHIN EACH IMMEDIATE CONTAINER: 10 DOSES
SPECIAL FEATURES: STERILE SUSPENSION OF THREE TYPES OF POLIOVIRUS; TYPE 1 (MAHONEY), TYPE 2 (MEF-1), AND TYPE 3 (SAUKETT); ONE 5 ML MULTIDOSE VIAL; 0.5 ML PER DOSE; EACH STERILE IMMUNIZING DOSE OF TRIVALENT VACCINE CONTIANS 40 D ANTIGEN UNITS OF TYPE 1, 8 D ANTIGEN UNITS
~1: OF TYPE 2 AND 32 D ANTIGEN OF TYPE 3 POLIOVIRUS; SHOULD BE ADMINISTERED INTRAMUSCULARLY OR SUBCUTANEOUSLY; VACCINE IS STABLE IF STORED IN THE REFRIGERATOR BETWEEN 2 DEG TO 8 DEG C; THERE ARE 10 DOSES IN THE VIAL
Related Searches:
IPOL
POLIOVIRUS VACCINE INACTIVATED,USP
NSN, MFG P/N
6505014910528
NSN
6505-01-491-0528
IPOL
POLIOVIRUS VACCINE INACTIVATED,USP
NSN, MFG P/N
6505014910528
NSN
6505-01-491-0528
MFG
SANOFI PASTEUR INC.
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: POLIOVIRUS VACCINE INACTIVATED MODIFIED 10 DOSE VIAL
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: POLIO VIRUS VACCINE, INACTIVATED
IMMEDIATE CONTAINER QUANTITY: 1
IMMEDIATE CONTAINER TYPE: VIAL
QUANTITY WITHIN EACH IMMEDIATE CONTAINER: 10 DOSES
SPECIAL FEATURES: STERILE SUSPENSION OF THREE TYPES OF POLIOVIRUS; TYPE 1 (MAHONEY), TYPE 2 (MEF-1), AND TYPE 3 (SAUKETT); ONE 5 ML MULTIDOSE VIAL; 0.5 ML PER DOSE; EACH STERILE IMMUNIZING DOSE OF TRIVALENT VACCINE CONTIANS 40 D ANTIGEN UNITS OF TYPE 1, 8 D ANTIGEN UNITS
~1: OF TYPE 2 AND 32 D ANTIGEN OF TYPE 3 POLIOVIRUS; SHOULD BE ADMINISTERED INTRAMUSCULARLY OR SUBCUTANEOUSLY; VACCINE IS STABLE IF STORED IN THE REFRIGERATOR BETWEEN 2 DEG TO 8 DEG C; THERE ARE 10 DOSES IN THE VIAL
Related Searches:
NDC49281-0860-10
POLIOVIRUS VACCINE INACTIVATED,USP
NSN, MFG P/N
6505014910528
NSN
6505-01-491-0528
NDC49281-0860-10
POLIOVIRUS VACCINE INACTIVATED,USP
NSN, MFG P/N
6505014910528
NSN
6505-01-491-0528
MFG
CARDINAL HEALTH INC. DBA CARDINAL HEALTH
Description
III PART NAME ASSIGNED BY CONTROLLING AGENCY: POLIOVIRUS VACCINE INACTIVATED MODIFIED 10 DOSE VIAL
III PROTECTIVE STORAGE FEATURE: SUBJECT TO DAMAGE BY FREEZING
III SUPPLEMENTARY FEATURES: POLIO VIRUS VACCINE, INACTIVATED
IMMEDIATE CONTAINER QUANTITY: 1
IMMEDIATE CONTAINER TYPE: VIAL
QUANTITY WITHIN EACH IMMEDIATE CONTAINER: 10 DOSES
SPECIAL FEATURES: STERILE SUSPENSION OF THREE TYPES OF POLIOVIRUS; TYPE 1 (MAHONEY), TYPE 2 (MEF-1), AND TYPE 3 (SAUKETT); ONE 5 ML MULTIDOSE VIAL; 0.5 ML PER DOSE; EACH STERILE IMMUNIZING DOSE OF TRIVALENT VACCINE CONTIANS 40 D ANTIGEN UNITS OF TYPE 1, 8 D ANTIGEN UNITS
~1: OF TYPE 2 AND 32 D ANTIGEN OF TYPE 3 POLIOVIRUS; SHOULD BE ADMINISTERED INTRAMUSCULARLY OR SUBCUTANEOUSLY; VACCINE IS STABLE IF STORED IN THE REFRIGERATOR BETWEEN 2 DEG TO 8 DEG C; THERE ARE 10 DOSES IN THE VIAL
Related Searches:
01-0590
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014912834
NSN
6505-01-491-2834
MFG
DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 500.000 MILLIGRAMS CIPROFLOXACIN HYDROCHLORIDE ACTIVE INGREDIENT
ADMINISTRATION: ORAL
FEATURES PROVIDED: INDIVIDUALLY SEALED
III PART NAME ASSIGNED BY CONTROLLING AGENCY: CIPROFLOXACIN TABLETS USP 500MG I.S. 30S PG
PRIMARY CONTAINER CONTENT QUANTITY: 30.000 TABLETS
PRIMARY CONTAINER TYPE: STRIP
PROTECTIVE STORAGE FEATURE: EXPIRATION DATED AND SUBJECT TO DAMAGE BY FREEZING
SPECIAL FEATURES: STORE BELOW 30 DEGREES C (86 DEGREES F);ARMY OWNED PRODUCT; THIS NSN REPRESENTS A PACKAGE SIZE PREPARED BY REPACKING BULK MATERIEL. THE NSN WAS CREATED TO PERMIT INVENTORY MANAGEMENT OF THE REPACKAGED DOSAGE FORM. THE NSN IS NOT PROCURABE; DO NOT
~1: REQUISITION CIPROFLOXACIN TABLETS, USP, 500 MG I.S. 30'S PACKAGE; THE LABEL FOR THIS NSN CONTAINS DIRECTIONS TO TAKE ONE DOSE EVERY 12 HOURS TO REDUCE THE CHANCE OF INFECTION AFTER EXPOSURE TO BIOLOGICAL AGENTS
Related Searches:
6505NCM010432
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014912834
NSN
6505-01-491-2834
6505NCM010432
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014912834
NSN
6505-01-491-2834
MFG
DEFENSE MEDICAL STANDARDIZATION BOARD
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 500.000 MILLIGRAMS CIPROFLOXACIN HYDROCHLORIDE ACTIVE INGREDIENT
ADMINISTRATION: ORAL
FEATURES PROVIDED: INDIVIDUALLY SEALED
III PART NAME ASSIGNED BY CONTROLLING AGENCY: CIPROFLOXACIN TABLETS USP 500MG I.S. 30S PG
PRIMARY CONTAINER CONTENT QUANTITY: 30.000 TABLETS
PRIMARY CONTAINER TYPE: STRIP
PROTECTIVE STORAGE FEATURE: EXPIRATION DATED AND SUBJECT TO DAMAGE BY FREEZING
SPECIAL FEATURES: STORE BELOW 30 DEGREES C (86 DEGREES F);ARMY OWNED PRODUCT; THIS NSN REPRESENTS A PACKAGE SIZE PREPARED BY REPACKING BULK MATERIEL. THE NSN WAS CREATED TO PERMIT INVENTORY MANAGEMENT OF THE REPACKAGED DOSAGE FORM. THE NSN IS NOT PROCURABE; DO NOT
~1: REQUISITION CIPROFLOXACIN TABLETS, USP, 500 MG I.S. 30'S PACKAGE; THE LABEL FOR THIS NSN CONTAINS DIRECTIONS TO TAKE ONE DOSE EVERY 12 HOURS TO REDUCE THE CHANCE OF INFECTION AFTER EXPOSURE TO BIOLOGICAL AGENTS
Related Searches:
CIPRO
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014912834
NSN
6505-01-491-2834
MFG
BAYER PHARMACEUTICALS CORPORATION
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 500.000 MILLIGRAMS CIPROFLOXACIN HYDROCHLORIDE ACTIVE INGREDIENT
ADMINISTRATION: ORAL
FEATURES PROVIDED: INDIVIDUALLY SEALED
III PART NAME ASSIGNED BY CONTROLLING AGENCY: CIPROFLOXACIN TABLETS USP 500MG I.S. 30S PG
PRIMARY CONTAINER CONTENT QUANTITY: 30.000 TABLETS
PRIMARY CONTAINER TYPE: STRIP
PROTECTIVE STORAGE FEATURE: EXPIRATION DATED AND SUBJECT TO DAMAGE BY FREEZING
SPECIAL FEATURES: STORE BELOW 30 DEGREES C (86 DEGREES F);ARMY OWNED PRODUCT; THIS NSN REPRESENTS A PACKAGE SIZE PREPARED BY REPACKING BULK MATERIEL. THE NSN WAS CREATED TO PERMIT INVENTORY MANAGEMENT OF THE REPACKAGED DOSAGE FORM. THE NSN IS NOT PROCURABE; DO NOT
~1: REQUISITION CIPROFLOXACIN TABLETS, USP, 500 MG I.S. 30'S PACKAGE; THE LABEL FOR THIS NSN CONTAINS DIRECTIONS TO TAKE ONE DOSE EVERY 12 HOURS TO REDUCE THE CHANCE OF INFECTION AFTER EXPOSURE TO BIOLOGICAL AGENTS
Related Searches:
CIPRO-30S
CIPROFLOXACIN TABLETS,USP
NSN, MFG P/N
6505014912834
NSN
6505-01-491-2834
MFG
BAYER PHARMACEUTICALS CORPORATION
Description
ACTIVE MEDICAMENT MEDICINAL STRENGTH: 500.000 MILLIGRAMS CIPROFLOXACIN HYDROCHLORIDE ACTIVE INGREDIENT
ADMINISTRATION: ORAL
FEATURES PROVIDED: INDIVIDUALLY SEALED
III PART NAME ASSIGNED BY CONTROLLING AGENCY: CIPROFLOXACIN TABLETS USP 500MG I.S. 30S PG
PRIMARY CONTAINER CONTENT QUANTITY: 30.000 TABLETS
PRIMARY CONTAINER TYPE: STRIP
PROTECTIVE STORAGE FEATURE: EXPIRATION DATED AND SUBJECT TO DAMAGE BY FREEZING
SPECIAL FEATURES: STORE BELOW 30 DEGREES C (86 DEGREES F);ARMY OWNED PRODUCT; THIS NSN REPRESENTS A PACKAGE SIZE PREPARED BY REPACKING BULK MATERIEL. THE NSN WAS CREATED TO PERMIT INVENTORY MANAGEMENT OF THE REPACKAGED DOSAGE FORM. THE NSN IS NOT PROCURABE; DO NOT
~1: REQUISITION CIPROFLOXACIN TABLETS, USP, 500 MG I.S. 30'S PACKAGE; THE LABEL FOR THIS NSN CONTAINS DIRECTIONS TO TAKE ONE DOSE EVERY 12 HOURS TO REDUCE THE CHANCE OF INFECTION AFTER EXPOSURE TO BIOLOGICAL AGENTS